Significantly higher peripheral insulin-like growth factor-1 levels in patients with major depressive disorder or bipolar disorder than in healthy controls a meta-Analysis and review under guideline of prisma

Medicine (United States)

Volumn 95, Issue 4, 2016, Pages

  Tu, Kun Yu ^a   Wu, Ming Kung ^a   Chen, Yen Wen ^b   Lin, Pao Yen ^b   Wang, Hung Yu ^c   Wu, Ching Kuan ^d   Tseng, Ping Tao ^a  

^a Tsyr Huey (Loving) Mental Hospital   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ARTICLE; BIPOLAR DISORDER; COGNITION; DIET RESTRICTION; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR DEPRESSION; MEDLINE; MENTAL PATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SYSTEMATIC REVIEW; BLOOD; CASE CONTROL STUDY; META ANALYSIS; METABOLISM; TIME FACTOR;

BIPOLAR DISORDER; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FASTING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; TIME FACTORS;

EID: 84957921770     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002411     Document Type: Article

References (57)

1. Tseng PT, Lee Y, Lin PY. Age-Associated decrease in serum glial cell line-derived neurotrophic factor levels in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:334-339
2. Chen YW, Lin PY, Tu KY, et al. Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-Analysis and systematic review. Neuropsychiatr Dis Treat. 2015;11:925-933
3. Munkholm K, Vinberg M, Kessing LV. Peripheral blood brainderived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-Analysis. Mol Psychiatry. 2015[Epub ahead of print].
4. Le Roith D. The insulin-like growth factor system. Exp Diabesity Res. 2003;4:205-212
5. Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol. 2010;70:384-396
6. Furlanetto RW. Insulin-like growth factor measurements in the evaluation of growth hormone secretion. Horm Res. 1990;33(Suppl 4):25-30
7. Weber-Hamann B, Blum WF, Kratzsch J, et al. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry. 2009;42:23-28
8. OKusky JR, Ye P, DErcole AJ. Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J Neurosci. 2000;20:8435-8442
9. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014;140:774-815
10. Bondy C, Lee WH. Correlation between insulin-like growth factor (IGF)-binding protein 5 and IGF-I gene expression during brain development. J Neurosci. 1993;13:5092-5104
11. Gluckman PD, Guan J, Williams C, et al. Asphyxial brain injury-The role of the IGF system. Mol Cell Endocrinol. 1998;140:95-99
12. Trejo JL, Carro E, Garcia-Galloway E, et al. Role of insulin-like growth factor I signaling in neurodegenerative diseases. J Mol Med (Berl). 2004;82:156-162
13. Aberg MA, Aberg ND, Hedbacker H, et al. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci. 2000;20:2896-2903
14. Schilling C, Blum WF, Heuser I, et al. Treatment with antidepressants increases insulin-like growth factor-I in cerebrospinal fluid. J Clin Psychopharmacol. 2011;31:390-392
15. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 1994;135:1753-1761
16. Kopczak A, Stalla GK, Uhr M, et al. IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol. 2015;25:864-872
17. Lesch KP, Rupprecht R, Muller U, et al. Insulin-like growth factor I in depressed patients and controls. Acta Psychiatr Scand. 1988;78:684-688
18. Li SX, Liu LJ, Xu LZ, et al. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology. 2013;38:2789-2799
19. Deuschle M, Blum WF, Strasburger CJ, et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology. 1997;22:493-503
20. Liu X, Zhang T, He S, et al. Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res. 2014;218:54-60
21. Kim YK, Na KS, Hwang JA, et al. High insulin-like growth factor-1 in patients with bipolar I disorder: a trait marker? J Affect Disord. 2013;151:738-743
22. Franz B, Buysse DJ, Cherry CR, et al. Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J Psychiatr Res. 1999;33:121-127
23. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335:1176-1181
24. Palomino A, Gonzalez-Pinto A, Martinez-Cengotitabengoa M, et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:29-33
25. Tseng PT, Cheng YS, Chen YW, et al. Increased levels of vascular endothelial growth factor in patients with major depressive disorder: a meta-Analysis. Eur Neuropsychopharmacol. 2015;25:1622-1630
26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12
27. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-Analysis detected by a simple, graphical test. BMJ. 1997;315:629-634
28. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62
30. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100
31. Stelzhammer V, Guest PC, Rothermundt M, et al. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. Eur Neuropsychopharmacol. 2013;23:1199-1207
32. Sievers C, Auer MK, Klotsche J, et al. IGF-I levels and depressive disorders: results from the Study of Health in Pomerania (SHIP). Eur Neuropsychopharmacol. 2014;24:890-896
33. Zenker S, Haverkamp F, Klingmuller D. Growth hormone deficiency in pituitary disease: relationship to depression, apathy and somatic complaints. Eur J Endocrinol. 2002;147:165-171
34. Lin F, Suhr J, Diebold S, et al. Associations between depressive symptoms and memory deficits vary as a function of insulin-like growth factor (IGF-1) levels in healthy older adults. Psychoneuroendocrinology. 2014;42:118-123
35. Bonne O, Gill JM, Luckenbaugh DA, et al. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J Clin Psychiatry. 2011;72:1124-1128
36. Lasaite L, Bunevicius R, Lasiene D, et al. Psychological functioning after growth hormone therapy in adult growth hormone deficient patients: endocrine and body composition correlates. Medicina (Kaunas). 2004;40:740-744
37. van Varsseveld NC, van Bunderen CC, Sohl E, et al. Serum insulinlike growth factor 1 and late-life depression: a population-based study. Psychoneuroendocrinology. 2015;54:31-40
38. Aggarwal VR, Macfarlane GJ, Tajar A, et al. Functioning of the hypothalamic-pituitary-Adrenal and growth hormone axes in frequently unexplained disorders: results of a population study. Eur J Pain. 2014;18:447-454
39. Eyre HA, Papps E, Baune BT. Treating depression and depressionlike behavior with physical activity: an immune perspective. Front Psychiatry. 2013;4:3
40. Szczesny E, Slusarczyk J, Glombik K, et al. Possible contribution of IGF-1 to depressive disorder. Pharmacol Rep. 2013;65:1622-1631
41. Agis-Balboa RC, Fischer A. Generating new neurons to circumvent your fears: the role of IGF signaling. Cell Mol Life Sci. 2014;71:21-42
42. Soubry A, Murphy S, Huang Z, et al. The effects of depression and use of antidepressive medicines during pregnancy on the methylation status of the IGF2 imprinted control regions in the offspring. Clin Epigenetics. 2011;3:2
43. Gann H, Riemann D, Stoll S, et al. Growth hormone response to growth hormone-releasing hormone and clonidine in depression. Biol Psychiatry. 1995;38:325-329
44. Pereira AC, McQuillin A, Puri V, et al. Genetic association and sequencing of the insulin-like growth factor 1 gene in bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2011;156:177-187
45. Bezchlibnyk YB, Xu L, Wang JF, et al. Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. Brain Res. 2007;1147:213-217
46. Krogh J, Rostrup E, Thomsen C, et al. The effect of exercise on hippocampal volume and neurotrophines in patients with major depression: a randomized clinical trial. J Affect Disord. 2014;165:24-30
47. Paslakis G, Blum WF, Deuschle M. Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression. Med Hypotheses. 2012;79:222-225
48. Malberg JE, Platt B, Rizzo SJ, et al. Increasing the levels of insulinlike growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007;32:2360-2368
49. Larnkjaer A, Arnberg K, Michaelsen KF, et al. Effect of milk proteins on linear growth and IGF variables in overweight adolescents. Growth Horm IGF Res. 2014;24:54-59
50. Squassina A, Costa M, Congiu D, et al. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol Res. 2013;73:1-7
51. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276
52. Saleh N, Moutereau S, Azulay JP, et al. High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology. 2010;75:57-63
53. Latalova K, Prasko J, Diveky T, et al. Cognitive impairment in bipolar disorder. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155:19-26
54. Bartke A. Growth hormone and aging: a challenging controversy. Clin Interv Aging. 2008;3:659-665
55. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14:20-39
56. Lin EJ, Lee NJ, Slack K, et al. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology. 2006;51:1129-1136
57. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol. 2001;51:317-324